<DOC>
	<DOCNO>NCT00077246</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ABI-007 , work different way stop tumor cell divide stop grow die . PURPOSE : This phase I/II trial study side effect best dose ABI-007 see well work treat patient stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>ABI-007 Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose dose-limiting toxicity paclitaxel ( albumin-stabilized Nanoparticle formulation ) ( ABI-007 ) patient chemotherapy-naïve stage IV non-small cell lung cancer . - Determine antitumor activity drug patient . - Determine safety tolerability drug patient . Secondary - Determine time disease progression patient treat drug . - Determine duration response patient treated drug . - Determine survival patient treated drug . OUTLINE : This open-label , dose-escalation study . - Phase I : Patients receive paclitaxel ( albumin-stabilized Nanoparticle formulation ) ( ABI-007 ) IV day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ABI-007 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive ABI-007 MTD ( determined phase I ) . Patients follow monthly 6 month every 3 month 1.5 year . PROJECTED ACCRUAL : A total 64 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IV nonsmall cell lung cancer Evidence inoperable local recurrence metastasis Bone metastases nonmeasurable disease may evidence metastasis Measurable disease document radiographically No evidence active brain metastasis leptomeningeal involvement PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 OR Karnofsky 80100 % Life expectancy More 12 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Hepatic AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin normal Alkaline phosphatase ≤ 2.5 time ULN ( unless due bone metastasis radiologic evidence hepatic metastasis ) Renal Creatinine ≤ 1.5 mg/dL Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 1 month study participation No prior allergy hypersensitivity study drug No concurrent active malignancy No preexist peripheral neuropathy grade 1 great No concurrent clinically significant illness No concurrent serious medical risk factor involve major organ system would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy metastatic disease More 4 week since prior cytotoxic chemotherapy No concurrent doxorubicin No concurrent taxanes No concurrent anthracyclines Endocrine therapy Not specify Radiotherapy At least 3 week since prior radiotherapy major bone marrowcontaining area More 4 week since prior radiotherapy except nontarget lesion Prior radiotherapy target lesion allow provide clear progression lesion since completion radiotherapy Surgery Not specify Other Prior epidermal growth factortargeted therapy allow More 4 week since prior investigational drug No concurrent enrollment another clinical trial investigational drug administer investigational procedure perform No concurrent treatment follow : Ritonavir Saquinavir Indinavir Nelfinavir No concurrent anticonvulsants No concurrent anticancer drug No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>